Journal of Global Infectious DiseasesOfficial Publishing of INDUSEM and OPUS 12 Foundation, Inc. Users online:224  
Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size     
Home About us Editors Ahead of Print Current Issue Archives Search Instructions Subscribe Advertise Login 

   Table of Contents     
Year : 2017  |  Volume : 9  |  Issue : 4  |  Page : 129-130
State of the globe: The global battle for survival against Mycobacterium tuberculosis

1 Department of Medicine, IGMC, Shimla, Himachal Pradesh, India
2 Department of Microbiology, Dr. RPGMC Kangra at Tanda, Kangra, Himachal Pradesh, India

Click here for correspondence address and email

Date of Web Publication12-Dec-2017

How to cite this article:
Chauhan V, Thakur S. State of the globe: The global battle for survival against Mycobacterium tuberculosis. J Global Infect Dis 2017;9:129-30

How to cite this URL:
Chauhan V, Thakur S. State of the globe: The global battle for survival against Mycobacterium tuberculosis. J Global Infect Dis [serial online] 2017 [cited 2022 Jan 17];9:129-30. Available from:

Mycobacterium tuberculosis (TB) is undoubtedly the most efficient killer of humans among all infections that they have ever encountered. This Bacillus is thriving worldwide despite unprecedented human progress in all areas of science and medicine over the past century. With its tremendous survival and adaptation capabilities, TB has infiltrated 30% of the human race on this planet.[1] With a masterly inactivity, it waits inside us for a lifetime. Whenever it gets a chance, it attacks us from the inside and finds its way to infect our fellow humans. Our knowledge, drug combinations, surveillance, and networking have all failed till now in the task to curb TB.

The global funding for TB care and prevention has more than doubled in 2017 (US$ 6.9 billion) compared to 2006 (US$ 3.3. billion). India stood out as a country in which the budget for TB was substantially increased in 2017 (to US$ 525 million, almost double the level of 2016), following political commitment from the Prime Minister to the goal of ending TB by 2025.[2]

The major issue we face now with TB is the emergency of multidrug resistance (MDR) and extensive drug resistance (XDR) strains of TB. In 2016, 490,000 new cases of MDR were registered and half of these were from India, China, and Russian Federation.[2] The global treatment success rate in 2016 for drug sensitive and MDR-TB was 83% and 54%, respectively, despite the substantial increase in funding for TB.[2]

The World Health Organization's (WHO) “End TB Strategy” and United Nations' (UN) “Sustainable Development Goals” (SDG) now share a common goal “To end the global TB epidemic.” It is good that the WHO and UN have realized the danger looming over the human race from this epidemic of TB, especially MDR-TB. The countries are now awakening to the reality that this Bacillus is not the problem of one country or one continent, but if not controlled now, it poses danger to the entire human race.

The global TB mortality and incidence are currently falling by 3% and 2% per year, respectively, but it needs to improve to 5% and 10%, respectively, to achieve the first milestone of “End TB Strategy' by 2020.”[2] With the current pace of funding, education, and health system readiness in high-burden countries, it is unlikely that this milestone will be achieved.

Universal MDR-TB detection in new cases is recommended by the WHO, but in high-burden countries, the facilities to subject all new TB cases for drug resistance testing are not easily available. One of the North Indian centers tested 244 consecutive culture-positive TB isolates for drug resistance. They reported rifampicin resistance of 71.1% and MDR of 53.5%.[3] These figures are alarming, though they are from a hospital-based sample.

In the fight against MDR-TB, two new drugs, namely bedaquiline and delamanid, have recently been added and at least 35 countries have introduced shorter regimens for treatment of MDR-TB. As part of efforts to improve outcomes for MDR/XDR-TB, 89 countries and territories have started using bedaquiline and 54 had used delamanid by June 2017.[2] There are 17 drugs in various trial phases and 12 vaccine candidates in clinical trials: 3 in Phase I and 9 in Phase II or III.[2] The shortened regimens of 9–12 months for MDR have been allowed in 2016 after sufficient evidence for effectiveness and cost efficiency. The earlier treatment regimens for MDR-TB were 20 months long.[2]

The global community is now gearing up for a final blow to the TB, and the years 2017 and 2018 are going to be landmark ones for worldwide efforts to end TB. In November 2017, the WHO is hosting the first Global Ministerial Conference on TB in Moscow with the theme of ending TB. In the second half of 2018, this will be followed by the first UN General Assembly high-level meeting on TB, at which a multisectoral approach to ending TB and an associated multisectoral accountability framework will be discussed by heads of state.[2]

The Bacillus has rapidly mutated taking advantage of poverty, crowding, poor health care, improper treatment, and incomplete regimens in the developing countries.

The emergence of MDR and XDR species aided by the ever-increasing socioeconomic gap is tilting the results in favor of the TB. On the other hand, gearing up of the WHO and UN to fight TB jointly with increased financing for End TB Strategy and SDG goals is the only hope for the human race in its effort to dominate this Bacillus. An epic global battle has now begun between the TB Bacillus and the human race for ultimate existence on this planet.

   References Top

WHO. Tuberculosis Fact Sheet Updated October, 2017. Available from: [Last accessed on 2017 Nov 19].  Back to cited text no. 1
WHO: Global Tuberculosis Report. Available from: [Last accessed on 2017 Nov 19].  Back to cited text no. 2
Sinha P, Srivastava GN, Gupta A, Anupurba S. Association of risk factors and drug resistance pattern in tuberculosis patients in North India. J Glob Infect Dis 2017;9:22-8.  Back to cited text no. 3

Correspondence Address:
Vivek Chauhan
IGMC, Shimla - 171 001, Himachal Pradesh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jgid.jgid_150_17

Rights and Permissions

This article has been cited by
1 Potential Plasticity of the Mannoprotein Repertoire Associated to Mycobacterium tuberculosis Virulence Unveiled by Mass Spectrometry-Based Glycoproteomics
Laure Tonini, Bashir Sadet, Alexandre Stella, David Bouyssié, Jérôme Nigou, Odile Burlet-Schiltz, Michel Rivière
Molecules. 2020; 25(10): 2348
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  


 Article Access Statistics
    PDF Downloaded46    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

Sitemap | What's New | Feedback | Copyright and Disclaimer | Contact Us
© 2008 Journal of Global Infectious Diseases | Published by Wolters Kluwer - Medknow
Online since 10th December, 2008